On endogenous Angiotensin II antagonism in hypertension

Hypertension

Volumn 68, Issue 3, 2016, Pages 552-554

  Ocaranza, María Paz ^a   Jalil, Jorge E ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE III; UNCLASSIFIED DRUG; DIPEPTIDYL PEPTIDASE IV;

ANTIHYPERTENSIVE ACTIVITY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; NONHUMAN; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; REPRODUCIBILITY; SYSTOLIC BLOOD PRESSURE; VASODILATATION; HUMAN;

ANGIOTENSIN II; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; HUMANS; HYPERTENSION;

EID: 84980018982     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07471     Document Type: Note

References (10)

1. Pang X, Shimizu A, Kurita S, Zankov DP, Takeuchi K, Yasuda-Yamahara M, Kume S, Ishida T, Ogita H, Novel therapeutic role for dipeptidyl peptidase III in the treatment of hypertension. Hypertension 2016 68 630 641. doi: 10.1161/HYPERTENSIONAHA.116.07357
2. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krähenbühl S, Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 2013 52 783 792. doi: 10.1007/s40262-013-0072-7
3. Marques FD, Melo MB, Souza LE, Irigoyen MC, Sinisterra RD, de Sousa FB, Savergnini SQ, Braga VB, Ferreira AJ, Santos RA, Beneficial effects of long-Term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats. Int J Hypertens 2012 2012 795452. doi: 10.1155/2012/795452
4. Santos SH, Andrade JM, Angiotensin 1-7: a peptide for preventing and treating metabolic syndrome. Peptides 2014 59 34 41. doi: 10.1016/j.peptides.2014.07.002
5. Ocaranza MP, Moya J, Barrientos V, Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. J Hypertens 2014 32 771 783. doi: 10.1097/HJH.0000000000000094
6. Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U, Apablaza F, Gonzalez L, Hernandez C, Varas M, Lopez R, Godoy I, Verdejo H, Chiong M, Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 2010 28 1054 1064
7. Lautner RQ, Villela DC, Fraga-Silva RA, Discovery and characterization of alamandine: a novel component of the renin-Angiotensin system. Circ Res 2013 112 1104 1111. doi: 10.1161/CIRCRESAHA.113.301077
8. Waumans Y, Baerts L, Kehoe K, Lambeir AM, De Meester I, The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis. Front Immunol 2015 6 387. doi: 10.3389/fimmu.2015.00387
9. Sufiun A, Rafiq K, Fujisawa Y, Rahman A, Mori H, Nakano D, Kobori H, Ohmori K, Masaki T, Kohno M, Nishiyama A, Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertens Res 2015 38 237 243. doi: 10.1038/hr.2014.173
10. Prajapati SC, Chauhan SS, Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J 2011 278 3256 3276. doi: 10.1111/j.1742-4658.2011.08275.x